Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The incidence and mortality of esophageal cancer are at the forefront in China, among which
the elderly patients account for a large proportion. Concurrent chemoradiotherapy is the
standard treatment for inoperable locally advanced esophageal cancer. Most elderly patients
with esophageal cancer cannot tolerate concurrent chemotherapy because of complications and
other reasons. Immunotherapy has definite efficacy and low toxicity in advanced esophageal
squamous cell carcinoma, and the results combined with radiotherapy have also been
preliminarily reported. Therefore, it is necessary to further explore the efficacy and safety
of radiotherapy combined with immunotherapy in elderly patients with esophageal cancer.